33 results
8-K
EX-99.1
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
of disease, while facilitating nerve repair after acute nerve injury, the strong positive Phase 3 results with the 30 mg/kg dose resulting in one week
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
Rapidly Shuts Down Activation of the ENTIRE Classical Complement Cascade on the Nerve to Prevent Acute Injury Classical Complement Drives Harmful
8-K
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
tissue damage in the early phase of disease, while facilitating nerve repair after acute nerve injury, the strong positive Phase 3 results with the 30
8-K
EX-99.1
dz55ynt iyqk2
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-99.1
p5q9nym
4 Oct 21
Departure of Directors or Certain Officers
4:06pm
8-K
EX-99.1
v0pp8w4ino
22 Jul 21
Regulation FD Disclosure
4:15pm
10-K
z9yf8f ns5j
25 Mar 21
Annual report
7:16am
8-K
EX-99.1
ufpj46roo54naa1yfwd
11 Jan 21
Regulation FD Disclosure
6:06am